David Drucker, MD
Interventional Cardiology · Newtown, PANPI 1730179854
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 84.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $30,951 and has fallen 74.3% since, to $7,952 in 2025.
Across 310 payments — averaging $268.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$71K
- Johnson & Johnson$7K
- Edwards Lifesciences$2K
- Medtronic$2K
- AstraZeneca$310
- E.r. Squibb & Sons, L.L.C.$264
- plus $2K from 23 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Consulting fees$35,05542%
- Speaking & faculty fees$31,23838%
- Travel & lodging$7,5599%
- Food & beverage$9,38411%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 113 | $70,504 |
| Johnson & Johnson | 40 | $6,818 |
| Edwards Lifesciences | 22 | $1,919 |
| Medtronic(2 entities) | 31 | $1,785 |
| AstraZeneca | 19 | $310 |
| E.r. Squibb & Sons, L.L.C. | 14 | $264 |
| Abbott | 6 | $232 |
| Abiomed | 5 | $227 |
| Bolton Medical Inc | 2 | $202 |
| Pfizer | 13 | $169 |
| Amgen | 8 | $119 |
| Biosense Webster, Inc. | 4 | $96 |
| Novartis | 6 | $94 |
| Cook Medical LLC | 4 | $86 |
| Terumo Medical Corporation | 1 | $77 |
| Merck | 4 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Novo Nordisk | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $33 |
| Kestra Medical Technology Services, Inc. | 1 | $30 |
| Recor Medical Inc | 1 | $24 |
| 180 Medical, Inc. | 1 | $24 |
| Bayer | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Shockwave Medical, Inc | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL CATHETER$26,563
- GENERAL - THERAPIES$18,855
- GENERAL VASCULAR INTERVENTION$8,557
- XARELTO$6,155
- GENERAL - STENTS$1,765
- COREVALVE EVOLUT R$783
- ELUVIA$750
- Edwards SAPIEN 3 Transcatheter Heart Valve$530
- GENERAL ATHERECTOMY$525
- LOTUS EDGE$439
- SAPIEN 3 Ultra RESILIA$348
- Ranger$250
- Endurant$240
- PASCAL$209
- TREO ABDOMINAL STENT-GRAFT SYSTEM$145
- Impella$133
- MitraClip$129
- Watchman$119
- GENERAL METALLIC STENTS$108
How this compares
$83,268 in reported general payments places this provider in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 308 | $396,147 |
| Repatha SureclickEvolocumab | 124 | $127,432 |
| EntrestoSacubitril/Valsartan | 51 | $73,564 |
| BrilintaTicagrelor | 53 | $65,433 |
| FarxigaDapagliflozin Propanediol | 47 | $47,580 |
| XareltoRivaroxaban | 34 | $43,466 |
| Praluent PenAlirocumab | 33 | $23,072 |
| Pitavastatin Calcium | 29 | $17,958 |
| Metoprolol Succinate | 695 | $12,828 |
| Carvedilol ErCarvedilol Phosphate | 19 | $11,273 |
| Rosuvastatin Calcium | 599 | $10,725 |
| CrestorRosuvastatin Calcium | 18 | $8,342 |
| LivaloPitavastatin Calcium | 14 | $7,540 |
| ClopidogrelClopidogrel Bisulfate | 390 | $6,868 |
| Atorvastatin Calcium | 528 | $6,750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $169 | $396,147308 claims |
| AstraZenecaBrilinta, Farxiga, Crestor | $310 | $121,356118 claims |
| NovartisEntresto | $94 | $73,56451 claims |
| Johnson & JohnsonXarelto | $6,818 | $43,46634 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $14 | $7,54014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Newtown
- George HeyrichNewtown$33K
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1M
- William GrayWynnewood$753K
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- James HarveyChambersburg$442K
- Taisei KobayashiPhiladelphia$384K
- Antonis PratsosBroomall$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.